Is Absci Corp (ABSI) overvalued? · rev $4.5M
Absci Corp (ABSI) is a biotechnology company listed on NASDAQ.
This page asks whether Absci Corp (ABSI) looks expensive on cached numbers — not a short thesis.
Latest reported ABSI revenue for 2024-12-31 was $4.5M. Net income was -$103.1M. Revenue was down 20.7% from 2023-12-31 to 2024-12-31. ABSI currently screens at market cap $1.13B.
ABSI currently screens at market cap $1.13B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next ABSI 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the ABSI stock page for the full model, not this heading.
Not investment advice.